DiaMedica Therapeutics
DMAC · Nasdaq · United States
Share price · DMAC
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when DMAC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Nov 2026-16.1%
- 3 Nov 2026+7.6%
Nothing announced by DMAC that day or the session before.
- 28 Oct 2026+13.0%
Nothing announced by DMAC that day or the session before.
- 20 Oct 2026+10.2%
- 21 Sep 2026+6.0%
Nothing announced by DMAC that day or the session before.
- 1 Jul 2026+5.7%
Nothing announced by DMAC that day or the session before.
- 29 Jun 2026+10.2%
Nothing announced by DMAC that day or the session before.
- 23 Jun 2026+6.6%
Nothing announced by DMAC that day or the session before.
- 26 May 2026+6.9%
Nothing announced by DMAC that day or the session before.
- 8 Apr 2026-5.5%
Nothing announced by DMAC that day or the session before.
Share of unusual movement by asset
For each asset, the share of DMAC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Rinvecalinase alfaevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 13% |
| Sessions with no dated event | — | 87% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | Tissue kallikrein-1 (KLK1)Protein / enzyme therapeutic | Acute Ischemic Stroke |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $9.2M | $6.8M+ $28M short-term inv. | $11M-$8.8M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $8.2M | $5.1M+ $38M short-term inv. | $10M-$8.1M operating cash flow | report ↗ |
| 2026-Q1 | — | $8.0M | $4.9M+ $46M short-term inv. | $10M-$9.1M operating cash flow | report ↗ |
| 2025-Q3 | — | $6.4M | $3.3M+ $52M short-term inv. | $8.6M-$6.5M operating cash flow | report ↗ |
| 2025-Q2 | — | $5.8M | $4.1M+ $26M short-term inv. | $7.7M-$7.6M operating cash flow | report ↗ |
| 2025-Q1 | — | $5.7M | $2.6M+ $34M short-term inv. | $7.7M-$7.2M operating cash flow | report ↗ |
| 2024-Q3 | — | $5.0M | $4.1M+ $46M short-term inv. | $6.3M-$4.5M operating cash flow | report ↗ |
| 2024-Q2 | — | $3.9M | $14M+ $40M short-term inv. | $5.1M-$4.5M operating cash flow | report ↗ |
| 2024-Q1 | — | $3.7M | $2.1M+ $44M short-term inv. | $5.2M-$6.7M operating cash flow | report ↗ |
| 2023-Q3 | — | $3.3M | $2.2M+ $44M short-term inv. | $4.5M-$4.8M operating cash flow | report ↗ |
| 2023-Q2 | — | $2.5M | $5.8M+ $35M short-term inv. | $4.5M-$5.0M operating cash flow | report ↗ |
| 2023-Q1 | — | $3.6M | $2.1M+ $27M short-term inv. | $5.3M-$5.1M operating cash flow | report ↗ |
| 2022-Q3 | — | $1.6M | $2.8M+ $33M short-term inv. | $3.1M-$2.4M operating cash flow | report ↗ |
| 2022-Q2 | — | $2.0M | $3.1M+ $35M short-term inv. | $3.4M-$2.5M operating cash flow | report ↗ |
| 2022-Q1 | — | $2.0M | $3.0M+ $38M short-term inv. | $3.5M-$3.9M operating cash flow | report ↗ |
| 2021-Q3 | — | $2.3M | $16M+ $32M short-term inv. | $3.5M-$3.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $25M | $16M+ $44M short-term inv. | $8.2M-$29M operating cash flow | report ↗ |
For fiscal year 2025, DiaMedica Therapeutics reported no disclosed revenue. R&D spend was $24.61M, up 29.1% YoY from $19.06M, with cash and equivalents of $15.65M. The company reported a net loss of $32.77M and a quarterly net burn of $32.77M.
DiaMedica continued clinical development of DM199 across its preeclampsia/fetal growth restriction and acute ischemic stroke programs. Interim results from Part 1a of the investigator-sponsored Phase 2 PE study indicated DM199 was safe and well-tolerated with no placental transfer, and preparations were underway for Part 1b. The company also held a pre-IND meeting with the FDA for its planned early-onset PE Phase 2 study, where the FDA requested an additional ePPND study; preliminary rabbit results showed an antibody response to DM199, leading the company to evaluate alternative models. For AIS, the Phase 2/3 ReMEDy2 trial remains designed to enroll approximately 300 participants at up to 100 global sites, with an interim analysis after 200 participants and a possible final sample size up to 728. In March 2026, Health Canada approved initiation of a Phase 2 study in early-onset preeclampsia, with a UK clinical trial application anticipated in the second quarter of 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $19M | $3.0M+ $41M short-term inv. | $6.1M-$22M operating cash flow | report ↗ |
| 2023-FY | — | $13M | $4.5M+ $48M short-term inv. | $4.8M-$19M operating cash flow | report ↗ |
| 2022-FY | — | $7.8M | $4.7M+ $29M short-term inv. | $3.4M-$12M operating cash flow | report ↗ |
| 2021-FY | — | $8.8M | $4.7M+ $40M short-term inv. | $3.4M-$12M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($2.5M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-10 | Pauls Dietrich John · director, President & CEO | Award / grant | 60,200 | — | — | Form 4 |
| 2026-06-01 | Krop Julie · Chief Medical Officer | Award / grant (derivative) | 67,500 | — | — | Form 4 |
| 2026-06-01 | Kellen Scott · CFO & Secretary | Award / grant (derivative) | 162,000 | — | — | Form 4 |
| 2026-06-01 | Pauls Dietrich John · director, President & CEO | Award / grant (derivative) | 380,000 | — | — | Form 4 |
| 2026-06-01 | Parsons James T. · director | Award / grant (derivative) | 51,189 | — | — | Form 4 |
| 2026-06-01 | Semba Charles Pauling · director | Award / grant (derivative) | 40,412 | — | — | Form 4 |
| 2026-06-01 | Lewis Tanya · director | Award / grant (derivative) | 40,412 | — | — | Form 4 |
| 2026-06-01 | O'Connor Daniel J. · director | Award / grant (derivative) | 40,412 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 98 reporting institutions held 11.8M shares ($79.0M, 21.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | COOPERMAN LEON G | 2,020,000 | $13.7M |
| 2 | BlackRock, Inc. | 1,856,187 | $12.6M |
| 3 | MILLENNIUM MANAGEMENT LLC | 935,592 | $6.3M |
| 4 | PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 875,000 | $5.9M |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 780,516 | $5.3M |
| 6 | STATE STREET CORP | 644,211 | $4.4M |
| 7 | FIRST MANHATTAN CO. LLC. | 455,000 | $3.1M |
| 8 | Bleichroeder LP | 382,317 | $2.6M |
| 9 | NORTHERN TRUST CORP | 338,526 | $2.3M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 333,456 | $2.3M |
| 11 | OSAIC HOLDINGS, INC. | 319,675 | $2.2M |
| 12 | LPL Financial LLC | 226,050 | $1.5M |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 203,459 | $1.4M |
| 14 | VANGUARD FIDUCIARY TRUST CO | 187,724 | $1.3M |
| 15 | CITADEL ADVISORS LLC | 145,724 | $987K |